Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab

This is a 48 week, single-arm study to evaluate the effect of mepolizumab on lung structure and functions evaluated using pulmonary MRI and CT imaging in 36 patients with COPD. Study treatment will be administered at a baseline visit and every 4 weeks, with clinic visits at baseline, week-12, week-24, and week-48. After providing written, informed consent, all study visits participants will have vital signs recorded and undergo pre- and post-bronchodilator spirometry, plethysmography, oscillometry, pre-bronchodilator forced exhaled nitric oxide (FeNO) and post-bronchodilator diffusing capacity of the lungs for carbon monoxide (DLco). Participants will undergo pre- and post-bronchodilator 129-Xe MRI and post-bronchodilator chest computed tomography (CT) (CT at Visits 1, 3, 4). Participants will complete St. George's Respiratory Questionnaire (SGRQ), Modified Medical Research Council (mMRC), COPD Assessment Test (CAT), Borg rating of perceived exertion questionnaire will be completed before and after the six-minute walk test (6MWT). Participants will have a blood draw for complete blood count (CBC). Participants will undergo sputum induction at Visits 1 and 4.